Safety and Immunogenicity of COVID-19 Vaccine in Population Aged 18 Years and Above

Summary

This is a randomized, blinded, positive-controlled study to evaluate the safety and immnunogenicity of Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001, in population aged 18 years old and above. 100 subjects will be recruited in this study, including 50 aged 18-59 years old and 50 aged 60 years old and above.

Timeline

Start

2022-07-19

Primary completion

2023-01-10

Completion

2023-12-01

Publications

• Tang R, Zeng Y, Zhou Y, Liang Q, Kang W, Yang Z, Zheng X, Zang X, Pan H, Jin J, Zhu F. Safety and immunogenicity of the SARS-CoV-2 LYB001 RBD-based VLP vaccine (CHO cell) phase 1 in Chinese adults: a randomized, double-blind, positive-parallel-controlled study. Expert Rev Vaccines. 2024 Jan-Dec;23(1):498-509. doi: 10.1080/14760584.2024.2337051. Epub 2024 May 2.

Drugs

Indications